Skip to Main content Skip to Navigation
Journal articles

Biomarkers associated with checkpoint inhibitors

Abstract : Checkpoint inhibitors (CPI), namely anti-CTLA4 and anti-PD1/PD-L1 antibodies, demonstrated efficacy across multiple types of cancer. However, only subgroups of patients respond to these therapies. Additionally, CPI can induce severe immune-related adverse events (irAE). Biomarkers that predict efficacy and toxicity may help define the patients who may benefit the most from these costly and potentially toxic therapies. In this study, we review the main biomarkers that have been associated with the efficacy (pharmacodynamics and clinical benefit) and the toxicity (irAE) of CPIs in patients.
Document type :
Journal articles
Complete list of metadatas

Cited literature [55 references]  Display  Hide  Download

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01359396
Contributor : Laurent Jonchère <>
Submitted on : Friday, October 7, 2016 - 10:04:05 AM
Last modification on : Wednesday, September 16, 2020 - 5:11:25 PM

File

Biomarkers Associated with Che...
Files produced by the author(s)

Identifiers

Citation

G. Manson, J. Norwood, A. Marabelle, H. Kohrt, R. Houot. Biomarkers associated with checkpoint inhibitors. Annals of Oncology, Elsevier, 2016, 27 (7), pp.1199--1206. ⟨10.1093/annonc/mdw181⟩. ⟨hal-01359396⟩

Share

Metrics

Record views

949

Files downloads

538